VKTX - CIK 0001607678
Viking Therapeutics, Inc. trades as VKTX and has a market capitalization of $3.23 B, making it the #1747 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$359.64M. This page tracks Viking Therapeutics, Inc. through 627 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13G | - | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-01 |
| Proxy materials | DEFA14A | 2026-04-01 |
| Proxy statement | DEF 14A | 2026-04-01 |
| SCHEDULE 13G/A | - | 2026-03-27 |
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled --
This study is fully enrolled and we look forward to announcing the results in the third quarter of 2026. We also expect to file an IND for ...
The largest companies sharing Viking Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Viking Therapeutics, Inc. (VKTX) has a market capitalization of $3.23 B as of 2026-06-10, ranking #1747 among US-listed companies.
Viking Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025.
In its latest fiscal year Viking Therapeutics, Inc. reported a net loss of $359.64M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.